Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196

Watchlist Manager
Shanghai Fosun Pharmaceutical Group Co Ltd Logo
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Watchlist
Price: 27.06 CNY -2.28%
Market Cap: 69.2B CNY
Have any thoughts about
Shanghai Fosun Pharmaceutical Group Co Ltd?
Write Note

Shanghai Fosun Pharmaceutical Group Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Fosun Pharmaceutical Group Co Ltd
Operating Income Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Fosun Pharmaceutical Group Co Ltd
SSE:600196
Operating Income
ÂĄ1.6B
CAGR 3-Years
-13%
CAGR 5-Years
-8%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ3.4B
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ5.8B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ4B
CAGR 3-Years
-1%
CAGR 5-Years
14%
CAGR 10-Years
3%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
-ÂĄ749.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Shanghai Fosun Pharmaceutical Group Co Ltd's Operating Income?
Operating Income
1.6B CNY

Based on the financial report for Jun 30, 2024, Shanghai Fosun Pharmaceutical Group Co Ltd's Operating Income amounts to 1.6B CNY.

What is Shanghai Fosun Pharmaceutical Group Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
0%

Over the last year, the Operating Income growth was -39%. The average annual Operating Income growth rates for Shanghai Fosun Pharmaceutical Group Co Ltd have been -13% over the past three years , -8% over the past five years .

Back to Top